claseprubart
claseprubart: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | Phase 3 |
FDA Decisions
FDA_MeetingFDA agreed to remove ANA screening/testing and reclassify hypothetical SLE risk to drug-induced lupus for all claseprubart trials.(DNTH)
Frequently asked questions
Who is developing claseprubart?
claseprubart is being developed by Dianthus Therapeutics, Inc. /DE/.
What is claseprubart's latest FDA decision?
The most recent tracked FDA decision for claseprubart is FDA_Meeting for FDA agreed to remove ANA screening/testing and reclassify hypothetical SLE risk to drug-induced lupus for all claseprubart trials., dated March 1, 2026.
Get deeper analysis on claseprubart
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis